Ishikawa H, Miller D D, Patil P N
College of Pharmacy, Division of Pharmacology, Ohio State University Lloyd M. Parks Hall, Columbus 43210-1291, USA.
Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):362-8. doi: 10.1007/BF00171069.
The alkylating agent isothiocyanatobenzyl imidazoline (IBI) was synthesized to investigate the unique receptor interacting properties of imidazolines. On the isolated rabbit iris sphincter, IBI produced concentration-dependent responses with an EC50 of 18 mumol/1, and at the highest concentration tested the maximum contraction of the tissue was 50% of the carbachol maximum. At equiactive concentrations with the similar washing procedure, the total duration of responses to IBI and carbachol was 24 and 3 min, respectively. After repeated washing, the sphineter relaxes to the control baseline of tone but, after reexposure to IBI for 6 h, failed to contract, indicating that desensitization or irreversible block has developed. Unlike with carbachol, the sphincter contraction to IBI was not affected by atropine 1 mumol/1, indomethacin 1 mumol/1, verapamil 10 mumol/1, or nifedipine 10 mumol/1. At a higher concentration of nifedipine and papaverine 100 mumol/1, the response to IBI was blocked. Furthermore, the contractile response to IBI was abolished by Ca++ removal from the medium. Under similar conditions, 26 +/- 8% of the maximum response to carbachol was preserved. Thus influx of extracellular as well as rise in intracellular Ca++ appears vital for the contractile response to IBI. IBI did not contract the iris dilator, but shifted the concentration-response curve to the alpha-adrenoceptor activator, phenylephrine, to the right with a reduction in the maximum response. The tissue failed to regain the sensitivity to phenylephrine after 6 h of repeated washing. Phentolamine and nifedipine provided a small but significant protection of the response to phenylephrine against the irreversible block by IBI. Based on chemical and pharmacological properties of IBI, it is concluded that the molecule acts in the rabbit as an irreversible agonist on unidentified receptors of the iris sphineter and an irreversible antagonist of multiple receptors on the iris dilator. These molecular properties of IBI are clearly different from that of the parent imidazoline molecule tolazoline.
合成了烷基化剂异硫氰酸苯甲酰咪唑啉(IBI),以研究咪唑啉独特的受体相互作用特性。在离体兔虹膜括约肌上,IBI产生浓度依赖性反应,EC50为18μmol/L,在测试的最高浓度下,组织的最大收缩幅度为卡巴胆碱最大收缩幅度的50%。在采用相似冲洗程序的等活性浓度下,对IBI和卡巴胆碱反应的总持续时间分别为24分钟和3分钟。反复冲洗后,括约肌松弛至对照基线张力,但在再次暴露于IBI 6小时后,无法收缩,表明出现了脱敏或不可逆阻断。与卡巴胆碱不同,括约肌对IBI的收缩不受1μmol/L阿托品、1μmol/L吲哚美辛、10μmol/L维拉帕米或10μmol/L硝苯地平的影响。在较高浓度的硝苯地平和100μmol/L罂粟碱作用下,对IBI的反应被阻断。此外,从培养基中去除Ca++可消除对IBI的收缩反应。在相似条件下,对卡巴胆碱最大反应的26±8%得以保留。因此,细胞外Ca++的内流以及细胞内Ca++的升高似乎对IBI的收缩反应至关重要。IBI不会使虹膜开大肌收缩,但会使α-肾上腺素能受体激动剂去氧肾上腺素的浓度-反应曲线右移,最大反应降低。反复冲洗6小时后,组织对去氧肾上腺素未能恢复敏感性。酚妥拉明和硝苯地平对去氧肾上腺素的反应提供了小但显著的保护,使其免受IBI的不可逆阻断。基于IBI的化学和药理学特性,得出结论:该分子在兔体内作为虹膜括约肌未明受体的不可逆激动剂以及虹膜开大肌多种受体的不可逆拮抗剂起作用。IBI的这些分子特性与母体咪唑啉分子妥拉唑啉明显不同。